Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.

Liam Gaziano; Luanluan Sun; Matthew Arnold; Steven Bell ORCID logo; Kelly Cho; Stephen K Kaptoge; Rebecca J Song; Stephen Burgess; Daniel C Posner ORCID logo; Katja Mosconi; +104 more... Cassianne Robinson-Cohen; Amy M Mason ORCID logo; Thomas R Bolton; Ran Tao; Elias Allara ORCID logo; Petra Schubert; Lingyan Chen; James R Staley; Natalie Staplin ORCID logo; Servet Altay; Pilar Amiano; Volker Arndt ORCID logo; Johan Ärnlöv ORCID logo; Elizabeth LM Barr ORCID logo; Cecilia Björkelund; Jolanda MA Boer ORCID logo; Hermann Brenner ORCID logo; Edoardo Casiglia ORCID logo; Paolo Chiodini ORCID logo; Jackie A Cooper; Josef Coresh ORCID logo; Mary Cushman ORCID logo; Rachel Dankner; Karina W Davidson ORCID logo; Renate T de Jongh ORCID logo; Chiara Donfrancesco; Gunnar Engström ORCID logo; Heinz Freisling; Agustín Gómez de la Cámara ORCID logo; Vilmundur Gudnason ORCID logo; Graeme J Hankey ORCID logo; Per-Olof Hansson ORCID logo; Alicia K Heath ORCID logo; Ewout J Hoorn ORCID logo; Hironori Imano ORCID logo; Simerjot K Jassal; Rudolf Kaaks; Verena Katzke ORCID logo; Jussi Kauhanen; Stefan Kiechl ORCID logo; Wolfgang Koenig ORCID logo; Richard A Kronmal ORCID logo; Cecilie Kyrø ORCID logo; Deborah A Lawlor; Börje Ljungberg ORCID logo; Conor MacDonald ORCID logo; Giovanna Masala ORCID logo; Christa Meisinger; Olle Melander; Conchi Moreno Iribas; Toshiharu Ninomiya ORCID logo; Dorothea Nitsch ORCID logo; Børge G Nordestgaard ORCID logo; Charlotte Onland-Moret ORCID logo; Luigi Palmieri ORCID logo; Dafina Petrova; Jose Ramón Quirós Garcia; Annika Rosengren ORCID logo; Carlotta Sacerdote; Masaru Sakurai; Carmen Santiuste; Matthias B Schulze ORCID logo; Sabina Sieri ORCID logo; Johan Sundström ORCID logo; Valérie Tikhonoff ORCID logo; Anne Tjønneland; Tammy Tong ORCID logo; Rosario Tumino; Ioanna Tzoulaki ORCID logo; Yvonne T van der Schouw ORCID logo; WM Monique Verschuren; Henry Völzke; Robert B Wallace; S Goya Wannamethee ORCID logo; Elisabete Weiderpass ORCID logo; Peter Willeit ORCID logo; Mark Woodward ORCID logo; Kazumasa Yamagishi ORCID logo; Raul Zamora-Ros ORCID logo; Elvis A Akwo; Saiju Pyarajan; David R Gagnon ORCID logo; Philip S Tsao ORCID logo; Sumitra Muralidhar; Todd L Edwards ORCID logo; Scott M Damrauer ORCID logo; Jacob Joseph ORCID logo; Lisa Pennells ORCID logo; Peter WF Wilson; Seamus Harrison; Thomas A Gaziano ORCID logo; Michael Inouye; Colin Baigent; Juan P Casas; Claudia Langenberg ORCID logo; Nick Wareham ORCID logo; Elio Riboli; J Michael Gaziano; John Danesh; Adriana M Hung ORCID logo; Adam S Butterworth ORCID logo; Angela M Wood; Emanuele Di Angelantonio ORCID logo; Emerging Risk Factors Collaboration/EPIC-CVD/Million Veteran Pro; (2022) Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses. Circulation, 146 (20). pp. 1507-1517. ISSN 0009-7322 DOI: 10.1161/CIRCULATIONAHA.122.060700
Copy

BACKGROUND: End-stage renal disease is associated with a high risk of cardiovascular events. It is unknown, however, whether mild-to-moderate kidney dysfunction is causally related to coronary heart disease (CHD) and stroke. METHODS: Observational analyses were conducted using individual-level data from 4 population data sources (Emerging Risk Factors Collaboration, EPIC-CVD [European Prospective Investigation into Cancer and Nutrition-Cardiovascular Disease Study], Million Veteran Program, and UK Biobank), comprising 648 135 participants with no history of cardiovascular disease or diabetes at baseline, yielding 42 858 and 15 693 incident CHD and stroke events, respectively, during 6.8 million person-years of follow-up. Using a genetic risk score of 218 variants for estimated glomerular filtration rate (eGFR), we conducted Mendelian randomization analyses involving 413 718 participants (25 917 CHD and 8622 strokes) in EPIC-CVD, Million Veteran Program, and UK Biobank. RESULTS: There were U-shaped observational associations of creatinine-based eGFR with CHD and stroke, with higher risk in participants with eGFR values <60 or >105 mL·min-1·1.73 m-2, compared with those with eGFR between 60 and 105 mL·min-1·1.73 m-2. Mendelian randomization analyses for CHD showed an association among participants with eGFR <60 mL·min-1·1.73 m-2, with a 14% (95% CI, 3%-27%) higher CHD risk per 5 mL·min-1·1.73 m-2 lower genetically predicted eGFR, but not for those with eGFR >105 mL·min-1·1.73 m-2. Results were not materially different after adjustment for factors associated with the eGFR genetic risk score, such as lipoprotein(a), triglycerides, hemoglobin A1c, and blood pressure. Mendelian randomization results for stroke were nonsignificant but broadly similar to those for CHD. CONCLUSIONS: In people without manifest cardiovascular disease or diabetes, mild-to-moderate kidney dysfunction is causally related to risk of CHD, highlighting the potential value of preventive approaches that preserve and modulate kidney function.


picture_as_pdf
Gaziano-etal_2022_Mild-to-moderate-kidney-dysfunction.pdf
subject
Accepted Version
Available under Creative Commons: 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads